公开(公告)号：US20200247899A1

公开(公告)日：2020-08-06

申请号：US16855703

申请日：2020-04-22

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20240317861A1

公开(公告)日：2024-09-26

申请号：US18539509

申请日：2023-12-14

Applicant: GENMAB A/S

Inventor： Isil ALTINTAS ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rik RADEMAKER ,  Paul PARREN ,  Bart DE GOEIJ

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/42

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/4258 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20210230296A1

公开(公告)日：2021-07-29

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200277397A1

公开(公告)日：2020-09-03

申请号：US16813167

申请日：2020-03-09

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  C12N15/79 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20180215827A1

公开(公告)日：2018-08-02

申请号：US15832337

申请日：2017-12-05

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD ,  Jan VAN DE WINKEL ,  David SATIJN ,  Paul PARREN ,  Aran Frank LABRIJN ,  Joyce MEESTERS ,  Janine SCHUURMAN ,  Edward N. VAN DEN BRINK

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20210030888A1

公开(公告)日：2021-02-04

申请号：US16978539

申请日：2019-03-06

Applicant: Genmab A/S

Inventor： Reshma Abdulla RANGWALA ,  Esther Cornelia Wilhelmina BREIJ ,  David SATIJN ,  Sandra VERPLOEGEN ,  Jantine BAKEMA ,  Oyewale O. ABIDOYE ,  Leonardo Viana NICACIO ,  Andreas LINGNAU

IPC: A61K47/68 ,  C07K16/36 ,  A61K9/00 ,  A61P35/00

Abstract: The invention provides methods and compositions for treating cancer, such as colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., colorectal cancer, non-small cell lung cancer, pancreatic cancer, head and neck cancer, bladder cancer, endometrial cancer, esophageal cancer and prostate cancer).

公开(公告)号：US20200062853A1

公开(公告)日：2020-02-27

申请号：US16316534

申请日：2017-07-14

Applicant: GENMAB A/S ,  BIONTECH AG

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  G01N33/569 ,  A61K39/395

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20190275149A1

公开(公告)日：2019-09-12

申请号：US16248402

申请日：2019-01-15

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US20190022243A1

公开(公告)日：2019-01-24

申请号：US16069395

申请日：2017-01-13

Applicant: GENMAB A/S

Inventor： Julia BOSHUIZEN ,  Esther BREIJ ,  Louise KOOPMAN ,  David SATIJN ,  Edward VAN DEN BRINK ,  Dennis VERZIJL ,  Rob DE JONG ,  Riemke VAN DIJKHUIZEN RADERSMA ,  Daniel PEEPER ,  Paul PARREN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00

Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.

公开(公告)号：US20180214549A1

公开(公告)日：2018-08-02

申请号：US15938961

申请日：2018-03-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  A61K2039/505 ,  A61K2121/00 ,  C07K16/2863 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.